Pomaglumetad

Pomaglumetad

Pomaglumetad (also known as LY2140023) is an investigational drug developed by Eli Lilly and Company for the treatment of schizophrenia and major depressive disorder (MDD). It is a selective agonist for the metabotropic glutamate receptor subtype 2/3 (mGlu2/3).

History

Pomaglumetad was first synthesized by researchers at Eli Lilly and Company. The drug entered clinical trials in the early 2000s, with the aim of providing a new treatment option for patients with schizophrenia and MDD.

Mechanism of Action

Pomaglumetad works by selectively activating the mGlu2/3 receptors in the brain. These receptors are part of the glutamate system, which plays a crucial role in regulating brain function. By activating these receptors, Pomaglumetad can help to normalize the function of the glutamate system, potentially reducing the symptoms of schizophrenia and MDD.

Clinical Trials

Several clinical trials have been conducted to evaluate the safety and efficacy of Pomaglumetad. However, the results have been mixed. Some studies have shown that the drug can significantly reduce the symptoms of schizophrenia and MDD, while others have found no significant benefit.

Future Development

Despite the mixed results from clinical trials, research into Pomaglumetad continues. Scientists are hopeful that with further study, they may be able to identify the specific patient populations that are most likely to benefit from this drug.

See Also

• Schizophrenia
• Major depressive disorder
• Metabotropic glutamate receptor
• Eli Lilly and Company

This article is a stub related to pharmacology. You can help WikiMD by expanding it!